---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-000611"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:22:50.646838+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Immunic appoints MS expert Dr. Richard Rudick to Board; Dr. Ossipow to retire at 2023 meeting

## Summary
- Dr. Rudick appointed as Class III director effective April 26, 2023; term ends at 2023 Annual Meeting.
- Received option to purchase 32,000 shares, vesting monthly over three years, exercise price at grant date closing price.
- Dr. Vincent Ossipow will not stand for re-election at 2023 Annual Meeting, continues until then; no disagreement cited.
- Board size increased from 7 to 8 directors upon Rudick's appointment.
- Rudick brings 35+ years of MS expertise from Cleveland Clinic and Biogen, expected to support vidofludimus calcium development.

## SEC filing metadata
- accession: 0001193805-23-000611
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/0001193805-23-000611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/e618552_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-000611
- JSON: https://secwatch.observer/filing/0001193805-23-000611.json
- Plain text: https://secwatch.observer/filing/0001193805-23-000611.txt

## Key facts
- Executive change
  Dr. Vincent Ossipow departed as Director at IMMUNIC, INC..
  - Action: plans to retire
  - Role: Director
  source text: Additionally, on April 26, 2023, Dr. Vincent Ossipow notified the Board that he plans to retire from the Board at the end of his current term and will not stand for re-election at the 2023 Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/0001193805-23-000611-index.htm
- Executive change
  Dr. Richard Rudick was appointed as Director at IMMUNIC, INC..
  - Action: appointed
  - Role: Director
  source text: On April 27, 2023, Immunic, Inc. (the “Company”) announced the appointment of Dr. Richard Rudick as a member of the Board of Directors (the “Board”) of the Company, effective as of April 26, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380523000611/0001193805-23-000611-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.